reported the design and synthesis of palbociclib-based PROTACs targeting CDK6 which induced the degradation of mutant CDK6 and effectively inhibited the proliferation of multiple myeloma (MM), leukaemia, and MCL cells. This evidence concerns the gene CDK6 and mantle cell lymphoma.